A non-toxic, nine residue peptide, NIVNVSLVK is shown to interfere with insulin fibrillation by various biophysical methods. Insulin undergoes conformational changes under certain stress conditions leading to amyloid fibrils. Fibrillation of insulin poses a problem in its long-term storage, reducing its efficacy in treating type II diabetes. The dissociation of insulin oligomer to monomer is the key step for the onset of fibrillation. The time course of insulin fibrillation at 62°C using Thioflavin T fluorescence shows an increase in the lag time from 120 min without peptide to 236 min with peptide. Transmission electron micrographs show branched insulin fibrils in its absence and less inter-fibril association in its presence. Upon incubation at 62°C and pH 2.6, insulin lost some α-helical structure as seen by Fourier transformed infra-red spectroscopy (FT-IR), but if the peptide is added, secondary structure is almost fully maintained for 3 h, though lost partially at 4 h. FT-IR spectroscopy also shows that insulin forms the cross beta structure indicative of fibrils beyond 2 h, but in the presence of the peptide, α-helix retention is seen till 4 h. Both size exclusion chromatography and dynamic light scattering show that insulin primarily exists as trimer, whose conversion to a monomer is resisted by the peptide. Saturation transfer difference nuclear magnetic resonance confirms that the hydrophobic residues in the peptide are in close contact with an insulin hydrophobic groove. Molecular dynamics simulations in conjunction with principal component analyses reveal how the peptide interrupts insulin fibrillation. In vitro hemolytic activity of the peptide showed insignificant cytotoxicity against HT1080 cells. The insulin aggregation is probed due to the inter play of two key residues, PheB24 and TyrB26 monitored from molecular dynamics simulations studies. Further new peptide based leads may be developed from this nine residue peptide.
References
[1]
Morris AM, Watzky MA, Finke RG (2009) Protein aggregation kinetics, mechanism, and curve-fitting: A review of the literature. Biochem. Biophys. Acta. 1794: 375–397.
[2]
Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75: 333–366.
[3]
Sipe JD, Cohen AS (2000) Review: History of the amyloid fibril. J. Struct. Biol. 130: 88–98.
[4]
McLaurin J, Yang DS, Yip CM, Fraser PE (2000) Review: Modulating factors in Amyloid-β fibril formation. J. Struct. Biol. 2000. 130: 259–270.
Alvarado MR, Merkel JS, Regan L (2000) A systematic exploration of the influence of the protein stability on amyloid fibril formation in vitro. Proc. Natl. Aca. Sci.USA 97: 8979–8984.
[7]
Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, et al. (1997) Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J. Mol. Biol. 273: 729–739.
[8]
Nelson R, Sawaya MR, Balbirnie M, Madsen A？, Riekel C, et al. (2005) Structure of the cross-beta spine of amyloid-like fibrils. Nature 435: 773–778.
[9]
Chang X, Jorgensen AM, Bardrum P, Led JJ (1997) Solution structures of the R6 human insulin hexamer. Biochemistry 36: 9409–9422.
[10]
Brange J, Andersen L, Laursen ED, Meyn G, Rasmussen E (1997) Toward understanding insulin fibrillation. J. Pharm. Sc. 86: 517–525.
[11]
Ahmad A, Millett IS, Doniach S, Uversky VN, Fink AL (2003) Partially folded intermediates in insulin fibrillation. Biochemistry 42: 11404–11416.
[12]
Ahmad A, Uversky VN, Hong D, Fink AL (2005) Early events in the fibrillation of monomeric insulin. J. Biol. Chem. 280: 42669–42675.
[13]
Yumlu S, Barany R, Eriksson M, Rocken C (2009) Localized insulin-derived amyloidosis in patients with diabetes mellitus: a case report. Hum Pathol. 40: 1655–1660.
[14]
Shikama Y, Kitazawa J, Yaqihashi N, Uehara O, Murata Y, et al. (2010) Localized amyloidosis at the site of repeated insulin injection in a diabetic patient. Intern Med. 49: 397–401.
[15]
Dische FE, Wernstedt C, Westermark GT, Westermark P, Pepys MB, et al. (1988) Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia 31: 158–161.
[16]
Pekar AH, Frank BH (1972) Conformation of proinsulin. A comparison of insulin and proinsulin self-association at neutral pH. Biochemistry 11: 4013–4016.
[17]
Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, et al. (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416: 507–511.
[18]
Kayed R, Head E, Thompson JL, Mclntire TM, Milton SC, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486–489.
[19]
Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, et al. (1998) Diffuson, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci 95: 6448–6453.
[20]
H？rd T, Lendel C (2012) Inhibition of amyloid formation. J. Mol. Biol. 421: 441–65.
[21]
Sciarretta KL, Gordon DJ, Meredith SC (2006) Peptide-based inhibitors of amyloid assembly. Methods Enzymol. 413: 273–312.
[22]
Brange J, Dodson GG, Edwards DJ, Holden PH, Whittingham JL (1997) A model of insulin fibrils derived from the x-ray crystal structure of a monomeric insulin (despentapeptide insulin). Proteins 27: 507–516.
[23]
Banerjee V, Das KP (2012) Modulation of pathway of insulin fibrillation by a small molecule helix inducer 2,2,2-trifluoroethanol. Colloids and Surf. B: Biointerfaces 92: 142–150.
[24]
Snijder EJ, Bredenbeek PJ, Dobbe JC, Thiel V, Ziebuhr J, et al. (2003) Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J. Mol. Biol. 331: 991–1004.
[25]
Tan Z, Shang S, Danishefsky SJ (2011) Rational development of a strategy for modifying the aggregatibility of proteins. Proc. Natl. Acad. Sci. USA 108: 4297–4302.
[26]
Zhou A, Stein PE, Huntington JA, Sivasothy P, Lomas DA, et al. (2004) How small peptides block and reverse serpin polymerisation. J. Mol. Biol. 342: 931–941.
[27]
Chalifour RJ, McLaughlin RW, Lavoie L, Morissette C, Tremblay N, et al. (2005) Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide. J. Biol. Chem. 278: 34874–34881.
[28]
Permanne B, Adessi C, Saborio GP, Fraga S, Frossard MJ, et al. (2002) Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J. 16: 860–862.
[29]
Pochan DJ, Schneider JP, Kretsinger J, Ozbas B, Rajagopal K, et al. (2003) Thermally reversible hydrogels via intramolecular folding and consequent self-assembly of a de novo designed peptide. J. Am. Chem. Soc. 125: 11802–11803.
[30]
El-Agnaf OM, Paleologou KE, Greer B, Abogrein AM, King JE, et al. (2004) A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J. 18: 1315–1317.
[31]
Hua QX, Weiss MA (2004) Mechanism of insulin fibrillation: the structure of insulin under amyloidogenic conditions resembles a protein-folding intermediate. J. Biol. Chem. 279: 21449–21460.
[32]
Pastor MT, Esteras CA, López PM (2005) Design of model systems for amyloid formation: lessons for prediction and inhibition. Curr. Opin. Struct. Biol. 15: 57–63.
[33]
Viet MH, Ngo ST, Lam NS, Li MS (2011) Inhibition of aggregation of amyloid peptides by beta-sheet breaker peptides and their binding affinity. J. Phys. Chem. B 115: 7433–7446.
[34]
Clore GM, Gronenborn AM (1982) Theory and applications of the transferred nuclear overhauser effect to the study of the conformations of small ligands bound to proteins J. Mag. Res. 48: 402–417.
[35]
Mayer M, Meyer B (1999) Characterization of ligand binding by saturation transfer difference NMR spectroscopy Angew. Chem. Int. Ed. 38: 1784–1788.
[36]
Bhunia A, Bhattacharjya S, Chatterjee S (2012) Applications of saturation transfer difference NMR in biological systems. Drug Discovery Today 17: 505–513.
[37]
Brange J, Langkjaer L, Havelund S, V？lund A (1992) Chemical stability of insulin. 1. Hydrolytic degradation during storage of pharmaceutical preparations. Pharm. Res. 9: 715–726.
[38]
Brange J, Havelund S, Hommel E, S？rensen E, Kühl C (1986) Neutral insulin solutions physically stabilized by addition of Zn2+. Diabetic Med. 3: 532–536.
[39]
(1982) US Pharmacopoeial Convention: Rockville, MD, 96–105.
[40]
Katakam M, Banga AK (1995) Aggregation of insulin and its prevention by carbohydrate excipients. PDA J. Pharm. Sc. Tech. 49: 160–165.
[41]
Blackshear PJ, Rohde TD, Palmer JL, Wigness BD, Rupp WM, et al. (1983) Glycerol prevents insulin precipitation and interruption of flow in an implantable insulin infusion pump. Diabetes Care 6: 387–392.
[42]
Grau U, Saudek CD (1987) Stable insulin preparation for implanted insulin pumps. Laboratory and animal trials. Diabetes 36: 1453–1459.
[43]
Thurow H, Geisen K (1984) Stabilisation of dissolved proteins against denaturation at hydrophobic interfaces. Diabetologia 27: 212–218.
[44]
Brewster ME, Hora MS, Simpkins JW, Bodor N (1991) Use of 2-hydroxypropyl-beta-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs. Pharm. Res. 8: 792–795.
[45]
Rabiee A, Ebrahim A, Navidpour L, Morshedi D, Ghasemi A, et al. (2011) Benzofuranone derivatives as effective small molecules related to insulin amyloid fibrillation: a structure-function study. Chem. Biol. Drug Des. 78: 659–666.
[46]
Wang JB, Wang YM, Zeng CM (2011) Quercetin inhibits amyloid fibrillation of bovine insulin and destabilizes preformed fibrils. Biochem. Biophys. Res. Comm. 415: 675–679.
[47]
Landreh M, Stukenborg JB, Willander H, S？der O, Johansson J, et al. (2012) Proinsulin C-peptide interferes with insulin fibril formation. Biochem. Biophys. Res. Comm. 418: 489–493.
[48]
Ban T, Hamada D, Hasegawa K, Naiki H, Goto Y (2003) Direct observation of amyloid fibril growth monitored by thioflavin T fluorescence. J. Biol. Chem. 278: 16462–16465.
[49]
Pocker Y, Biswas SB (1980) Conformational dynamics of insulin in solution. Circular dichroic studies. Biochemistry 19: 5043–5049.
[50]
Dong A, Matsuura J, Allison SD, Chrisman E, Manning MC, et al. (1996) Infrared and circular dichroism spectroscopic characterization of structural differences between beta-lactoglobulin A and B. Biochemistry. 35: 1450–1457.
[51]
Das KP, Choo LP, Petrash MJ, Surewicz WK (1999) Insight into the secondary structure of non-native proteins bound to a molecular chaperone alpha-crystallin: an isotope edited infrared spectroscopic study. J. Biol. Chem. 274: 33209–33212.
[52]
Surewicz WK, Mantsch HH, Chapman D (1993) Determination of protein secondary structure by Fourier transform infrared spectroscopy: a critical assessment. Biochemistry 32: 389–394.
[53]
Banerjee V, Das KP (2013) Interaction of silver nanoparticles with proteins: A characteristic protein concentration dependent profile of SPR signal. Collods Surf B Biointerfaces 111: 71–79.
[54]
Bouchard M, Zurdo J, Nettleton EJ, Dobson CM, Robinson CV (2000) Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Science 9: 1960–1967.
[55]
Vestergaard B, Groenning M, Roessle M, Kastrup JS, van de Weert M, et al. (2007) A helical structural nucleus is the primary elongating unit of insulin amyloid fibrils. PLoS Biology 5: e134.
[56]
Nielsen L, Khurana R, Coats A, Frokjaer S, Brange J, et al. (2001) Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry 40: 6036–6046.
[57]
Wang S, Zhang C, Nordeen SK, Shapiro DJ (2007) In vitro fluorescence anisotropy analysis of the interaction of full-length SRC1a with estrogen receptors alpha and beta supports an active displacement model for coregulator utilization. J. Biol. Chem. 282: 2765–2775.
[58]
Wi S, Pancoska P, Keiderling TA (1998) Predictions of protein secondary structures using factor analysis on Fourier transform infrared spectra: effect of Fourier self-deconvolution of the amide I and amide II bands Biospectroscopy. 4: 93–106.
[59]
Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, et al. (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65: 712–725.
[60]
Schneidman DD, Inbar Y, Nussinov R, Wolfson HJ (2005) PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Research 33: W363–W367.
[61]
Desmond Molecular Dynamics System, version 2.2 (2009) D. E. Shaw Research, New York, NY. Maestro-Desmond Interoperability Tools, version 2.2, (2009) Schr？dinger, New York, NY.
[62]
Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79: 926–935.
[63]
Shan Y, Klepeis JL, Eastwood MP, Dror RO, Shaw DE (2005) Gaussian split Ewald: A fast Ewald mesh method for molecular simulation. J. Chem. Phys. 122: 54101.
[64]
Tuckerman M, Berne BJ, Martyna GJ (1992) Reversible multiple time scale molecular dynamics. J. Chem. Phys. 97: 1990–2001.
[65]
Vincent K, Gunsteren WF, Hünenberger PH (2001) A Fast SHAKE Algorithm to Solve Distance Constraint Equations for Small Molecules in Molecular Dynamics Simulations J. Comput. Chem. 22: 501–508.
[66]
Spoel DVD, Lindahl E, Hess B, Groenhof G, Mark AE, et al.. (2005) GROMACS: Fast, flexible, and free. J. Comput. Chem. DOI: 10.1002/jcc.20291.
[67]
BioLuminate, version 1.0 (2012) Schr？dinger, LLC, New York, NY.
